CDK4 and Wilson disease: The mechanistic synergy demonstrated in other tumour types plus the promising clinical trial results of LPS patients treated with CDK4/6 inhibitor monotherapy [106] has now provided the rationale for the phase II clinical evaluation of the CDK4/6 inhibitor palbociclib combined with PD-1 blockade (INCMGA00012) in patients with advanced WD/DDLPS (NCT04438824).